Extramedullary Plasmacytoma of the Head and Neck Region in a Single Institution.

OBJECTIVE

The authors analyzed the clinical characteristics and treatment methods of patients with extramedullary plasmacytoma treated by the same treatment team at a single institution for 24 years and identified factors affecting the prognosis of patients.

PATIENTS AND

METHODS

The study enrolled 10 patients with a final diagnosis of extramedullary plasmacytoma of the head and neck region in a single institution from January 2001 to December 2024.

RESULTS

Of the 10 patients with extramedullary plasmacytoma (57.9±21.9 y, 8 male), 7 had tumors in the nasal cavity and 1 each in the tonsil, larynx, and hard palate. The mean tumor size was 3.4±2.7 cm (range, 1.4-9.0 cm). According to the staging system, 7 patients had stage 1 tumor, 3 had stage 3, and none had stage 2. Combination treatment with radiotherapy and surgery was the most common (70%). The mean dose of radiotherapy was 46.7±5.5 Gy. The 5-year relapse-free survival rate and 5-year survival rate of extramedullary plasmacytoma of the head and neck regions were 60% and 80%. The only statistically significant finding was that higher-stage extramedullary plasmacytoma was associated with worse overall survival.

CONCLUSION

The authors recommend the combination of radiotherapy and surgery for extramedullary plasmacytoma of the head and neck region when there are no major cosmetic or functional concerns associated with surgery.